Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2001-07-02
2008-11-25
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C514S012200, C530S350000, C530S387300
Reexamination Certificate
active
07455835
ABSTRACT:
The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.
REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5624823 (1997-04-01), Sachs et al.
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 5708037 (1998-01-01), Yagita
patent: 5747034 (1998-05-01), de Boer et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5773253 (1998-06-01), Linsley et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5851795 (1998-12-01), Linsley et al.
patent: 5885579 (1999-03-01), Linsley et al.
patent: 5885796 (1999-03-01), Linsley et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 5958403 (1999-09-01), Strom et al.
patent: 5968510 (1999-10-01), Linsley et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 5993800 (1999-11-01), Linsley et al.
patent: 6040292 (2000-03-01), Sommer
patent: 6090914 (2000-07-01), Linsley et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 6689803 (2004-02-01), Hunter
patent: 6750334 (2004-06-01), Gray et al.
patent: 7179466 (2007-02-01), Le et al.
patent: 2002/0039577 (2002-04-01), Townsend et al.
patent: 2002/0182211 (2002-12-01), Peach et al.
patent: 2003/0083246 (2003-05-01), Cohen et al.
patent: 2005/0214313 (2005-09-01), Peach et al.
patent: 0 613 944 (1994-09-01), None
patent: 0 682 039 (1995-11-01), None
patent: WO 93/00431 (1993-01-01), None
patent: WO 93/19767 (1993-10-01), None
patent: WO94/01547 (1994-01-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 94/29436 (1994-12-01), None
patent: WO95/06481 (1995-03-01), None
patent: WO95/28957 (1995-11-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 95/33823 (1995-12-01), None
patent: WO 95/34320 (1995-12-01), None
patent: WO 96/14865 (1996-05-01), None
patent: WO 96/23071 (1996-08-01), None
patent: WO/ 97/28267 (1997-08-01), None
patent: WO 98/31820 (1998-07-01), None
patent: WO 98/33513 (1998-08-01), None
patent: WO 98/56417 (1998-12-01), None
patent: WO 00/23115 (2000-04-01), None
patent: WO 01/54732 (2001-08-01), None
patent: WO 01/90122 (2001-11-01), None
patent: WO 01/92337 (2001-12-01), None
patent: WO 02/02638 (2002-01-01), None
U.S. Appl. No. 60/214,065.
Borigini et al., Bailliere's Clinical Rheumatology, 1995, 9: 689-710.
Battleman, David S. et al., “HSV-1 Vector-Mediated Gene Transfer of the Human Nerve Growth Factor Receptor p75hNGFRDefines High Affinity NGF Binding,”The Journal of Neuroscience, Mar. 1993, 13(3):941-51. (Exhibit 6).
Broach, James R., “Construction of High Copy Yeast Vectors Using 2-μm Circle Sequences,”Methods in Enzymology, 1983, 101:307-25. (Exhibit 7).
Byrn, Randal A. et al., “Characterization of In Vitro Inhibition of Human Immunodeficiency Virus By Purified Recombinant CD4,”Journal of Virology, Oct. 1989, 63(10):4370-5. (Exhibit 8).
Carroll, R. et al., “SZ 401 Construction and Characterization of Replication-Defective HIV-1 Packaging Cell Lines,”Journal of Cell Biochemistry, 1993, 17E:241. (Exhibit 9).
Clarke, Louise et al., “Selection Procedure for Isolation of Centromere DNAs fromSaccharomyces cerevisiae,”Methods in Enzymology, 1983, 101:300-7. (Exhibit 10).
Cohen, Stanley N. et al., “Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation ofEscherichia coliby R-Factor DNA,”Proc. Nat'l. Acad. Sci, USA, Aug. 1972, 69(8):2110-4. (Exhibit 11).
Dariavach, Piona et al., “Human Ig Superfamily CTLA-4 Gene: Chromosomal Localization and Identity of Protein Sequence Between Murine and Human CTLA-4 Cytoplasmic Domains,”Eur. J. Immunol., 1988, 18:1901-5. (Exhibit 12).
Dash, Bret et al., “Deletion of a Single N-Linked Glycosylation Site From the Transmembrane Envelope Protein of Human Immunodeficiency Virus Type 1 Stops Cleavage and Transport of gp160 Preventingenv-mediated Fusion,”Journal of General Virology, 1994, 75:1389:97. (Exhibit 13).
Davison, Elliott, “Obtaining Infectious Virus From Recombinant Plasmids” in Molecular Virology: A Practical Approach. Chapter 7 (IRL Press, New York, NY, 1993), pp. 184-186. (Exhibit 14).
Falk, Kirsten et al., “Both Human and Mouse Cells Expressing H-2Kband Ovalbumin Process the Same Peptide, SIINFEKL,”Cellular Immunology, 1993, 150:447-52. (Exhibit 15).
FDA. CDER Guideline for the Clinical Evaluation of Anti-Inflammatory and Antirheumatic Drugs. Apr. 1998. (Exhibit 16).
FDA. Guidance for Industry: Clinical Development Programs for Drugs, Devices and Biological Products for the Treatment of Rheumatoid Arthritis (RA). Feb. 1999. (Exhibit 17).
Felson, David T. et al., “The American College of Rheumatology Preliminary Core Set of Disease Activity Measures for Rheumatoid Arthritis Clinical Trials,”Arthritis and Rheumatism, Jun. 1993, 36(6):729-40. (Exhibit 18).
Felson, David T. et al., “American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis,”Arthritis and Rheumatism, Jun. 1995, 38(6):727-35. (Exhibit 19).
Fiers, W. et al., “Complete Nucleotide Sequence of SV40 DNA,”Nature, May 1978, 273:113-20. (Exhibit 20).
Fries, James F. et al., “The Dimensions of Health Outcomes: The Health Assessment Questionnaire, Disability and Pain Scales,”Journal of Rheumatology, 1982, 9(5):789-93. (Exhibit 21).
Fujikawa, Kiyomi et al., “Nuclear Localization and Transforming Activity of Human Papillomavirus Type 16 E7-β-Galactosidase Fusion Protein: Characterization of the Nuclear Localization Sequence,”Virology, 1994, 204:789-93. (Exhibit 22).
Gerard, C. et al., “Production and Characterization of Polyclonal Antibodies Recognizing the Intracytoplasmic Third Loop of the 5-Hydroxytryptamine1AReceptor,”Neuroscience, 1994, 62(3):721-39. (Exhibit 23).
Goeddel, David V. et al., “Synthesis of Human Fibroblast Interferon byE. coli,” Nucleic Acids Research, 1980, 8(18):4057-74. (Exhibit 24).
Greene, JoAnne L. et al., “Covalent Dimerization of CD28/CTLA-4 and Oligomerization of CD80/CD86 Regulate T Cell Costimulatory Interactions,”The Journal of Biological Chemistry, Oct. 25, 1996, 271(43):26762-71. (Exhibit 25).
Hansen, John A. et al., “Monoclonal Antibodies Identifying a Novel T-Cell Antigen and Ia Antigens of Human Lymphocytes,”Immunogenetics, 1980, 10:247-60. (Exhibit 26).
Hartley, R. D. et al., “Toxic Metabolites ofAspergillus Flavus,” Nature, Jun. 15, 1963, 198:1056-8. (Exhibit 27).
Hess, B. et al., “Cooperation of Glycolytic Enzymes,”Advances in Enzyme Regulation, 1969, 7:149-67. (Exhibit 28).
Hitzeman, Ronald A. et al., “Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique,”The Journal of Biological Chemistry, 1980, 255(24):12073-80. (Exhibit 29).
Holland, Michael J. and Janice P. Holland, “Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase,”Biochemistry, Nov. 1978, 17(23):4900-7. (Exhibit 30).
Ikeda, Toshido et al., “Isolation of a cDNA Encoding the Chicken p50B/p97 (Lyt-10) Transcription Factor,”Gene, 1994, 138:193-6. (Exhibit 31).
Johnsson, Bo et al., “Immobilization of Proteins to a Carboxymethyldextran-Modified Gold Surface for Biospecific Interaction Analysis in Surface Plasmon Resonance Sensors,”Anal Biochem, Nov. 1991, 198:268-77. (Exhibit 32).
Jones, Nancy H. et al., “Isolation of Complementary DNA Clones Encoding the Human Lymphocyte Glycoprotein T1/Leu-1,”Nature, Sep. 1986, 323:346-9. (Exhibit 33).
Karin, Michael and Robert I. Richards, “Human Metallothionein Genes—Primary Structure of the Metallothionein-II Gene and a Related Procesed Gene,”Nature, Oct. 1982, 299(5886):797-802. (Exhibit 34).
Khi
Bajorath Jurgen
Becker Jean-Claude
Carr Suzette
Cohen Robert
Hagerty David
Bristol--Myers Squibb Company
Ouspenski Ilia
Parlet Nickki L.
Sher Audrey
LandOfFree
Methods for treating immune system diseases using a soluble... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating immune system diseases using a soluble..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating immune system diseases using a soluble... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4036280